Kirchgraber Paul R
CIK 0001791393
CEO, Covance Drug Development
Filings
11
Latest May 23, 2023
Issuers covered
1
Showing
11 of 11
Page 1
Track record
2 of 2 open-market trades scored (100% price coverage). Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 2 | 50% | +3.2% | +3.2% | +13.2% | -6.8% |
| 90 days | 2 | 50% | -1.3% | -1.3% | +11.6% | -14.3% |
| 180 days | 2 | 0% | -7.1% | -7.1% | -1.5% | -12.7% |
| 365 days | 2 | 0% | -6.8% | -6.8% | -2.6% | -11.0% |
Issuers
Companies where Kirchgraber Paul R has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| LH | Laboratory Corp of America Holdings | 11 | May 23, 2023 |
All filings
11 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|